CDSCO Cancels Cosmetic Import Registration of Indian Agent for Proteos Biotech

Published On 2025-08-11 10:15 GMT | Update On 2025-08-11 19:14 GMT

New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has cancelled the Cosmetic Registration Certificate No. RC/COS-003595, held by NKG Advisory Business and Consulting Services Private Limited, for the import of cosmetic products manufactured by Proteos Biotech S.L, Spain.

According to the Office Memorandum issued on 4 August 2025 by the Cosmetics Division of CDSCO, the Indian agent, NKG Advisory Business and Consulting Services Private Limited, had submitted a Post Approval Change Request on 6 February 2025, followed by an e-receipt dated 28 April 2025, seeking surrender of the certificate.

The firm stated that the manufacturer, Proteos Biotech S.L, decided to discontinue the registration due to “business and administrative reasons” and would not be importing any cosmetic products registered under the said certificate into India.

The registration certificate, originally issued on 3 December 2022, was valid up to 1 December 2027 and covered the import of cosmetics registered by the Spanish manufacturer. With the company’s request, the CDSCO formally cancelled the registration.

The notice, signed by the Drugs Controller General of India (DCGI), Dr. Rajeev Singh Raghuvanshi, has been circulated to all zonal, sub-zonal, and port offices of CDSCO. A copy of the memorandum has also been shared with Proteos Biotech S.L via email.

The CDSCO memorandum stated, “As per the firm’s request, the registration certificate vide RC No. RC/COS-003595 dated 03.12.2022 pertaining to NKG Advisory Business and Consulting Services Private Limited has been cancelled."

Also Read: CDSCO Panel Accepts Phase I Trial Data for Intas' Denosumab Biosimilar

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Cancels Cosmetic Import Registration of Indian Agent for Proteos Biotech

Similar News

Torrent Pharma Receives SEC Approval to Market Alogliptin-Metformin FDC, Asked to Conduct Phase IV Trial

CDSCO Panel Seeks More Toxicity Data from Macleods on Semaglutide Injection Pre-Filled Pens

Unique Pharma Asked To Revise BE Study Protocol for Cilnidipine-Metoprolol FDC

Beta Drugs' Methotrexate Oral Solution Gets SEC Manufacturing, Marketing Nod

Biocon Told to Submit Detailed Toxicity, SAE Data on Semaglutide Prefilled Pen After Animal Deaths

CDSCO Panel Clears Eli Lilly's Tirzepatide for Phase IV Clinical Trial in India

CDSCO Panel Rejects Pure and Cure's Empagliflozin-Based FDC, Flags Risk of UTI, Genital Mycosis

Dr. Reddy's Labs Gets CDSCO Panel Nod to Manufacture, Market Semaglutide Injection